Series J J, Caslake M J, Kilday C, Cruickshank A, Demant T, Packard C J, Shepherd J
University Department of Biochemistry, Royal Infirmary, Glasgow, U.K.
Atherosclerosis. 1988 Feb;69(2-3):233-9. doi: 10.1016/0021-9150(88)90019-6.
This study examined the effect of single dose etofibrate (1.0 g/day) on plasma lipids and lipoproteins in a group of eleven hypercholesterolemic individuals. The drug lowered plasma triglyceride and cholesterol by 32% and 14%, respectively (P less than 0.005). The cholesterol reduction came from a decrement in both VLDL and LDL. The cholesterol content of HDL did not change although its mass as determined by analytical ultracentrifugation rose by 29%. LDL metabolism was followed before and during drug therapy. Treatment increased catabolism of this lipoprotein by 14%, without affecting synthesis. The increased clearance resulted from activation (64%) of the LDL receptor pathway. There was a reciprocal decrease in the amount of lipoprotein channelled into the receptor-independent route.
